

Doxepin

Selected References:

- American College of Obstetricians and Gynecologists (ACOG). 2018. Committee Opinion No. 753: Assessment and Treatment of Pregnant Women with Suspected or Confirmed Influenza. *Obstet Gyn* 132(4):e169-e173.
- Aoki FY, et al. 2013. The use of antiviral drugs for influenza: A foundation document for practitioners. *Can J Infect Dis Med Microbiol.* 24(Suppl C) :1-15.
- Beau A-B, et al. 2014. Safety of oseltamivir during pregnancy: a comparative study using the EFEMERIS database. *BJOG.* 121(7):895-900. 1-25.

¿Preguntas? Llame al [866.626.6847](tel:866.626.6847) | Texto [855.999.3525](tel:855.999.3525) | Correo electrónico o chat en [MotherToBaby.org](https://www.MotherToBaby.org) .

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de mayo de 2024.

Doxepin

Selected References:

- Ahn KH, et al. 2015. Pregnancy outcomes with paternal exposure to finasteride, a synthetic 5-alpha-reductase inhibitor: a case-series. *J Clin Toxicol* 5:2
- AlSaad D, et al. 2018. Finasteride use during pregnancy and early neonatal outcome: a case report. *Int J Clin Pharm* 40(4): 803-805.
- Amory JK, et al. 2007. The effect of 5- alpha-reductase inhibition with dutasteride and finasteride on semen parameters and serum hormones in healthy men. *J Clin Endocrinol Metab* 92:1659-1665.
- Anderson CA, Clark RL. 1990. External genitalia of the rat: normal development and the histogenesis of 5 alpha-reductase inhibitor-induced abnormalities. *Teratology*;42:483-496.
- Bowman CJ, et al. 2003. Effects of in utero exposure to finasteride on androgen-dependent reproductive

development in the male rat. *Toxicol Sci*; 74:393-406.

- Carlin JR, et al. 1992. Disposition and pharmacokinetics of (14C) finasteride after oral administration in humans. *Drug Metab Dispos Biol Fate Chem*; 20:148-55.
- Cather JC, et al. 1999. Finasteride - An update and review. *Cutis* 64:167-172.
- Ciotta L, et al. 1995. Clinical and endocrine effects of finasteride, a 5(alpha)-reductase inhibitor, in women with idiopathic hirsutism. *Fertil Steril* 64:299-306.
- Clark RL, Anderson CA, Prahallada S et al: Critical developmental periods for effects on male rat genitalia induced by finasteride, a 5(alpha)-reductase inhibitor. *Toxicol Appl Pharmacol* 119:34-40.
- Clark RL, et al. 1990. External genital abnormalities in male rats exposed in utero to finasteride, a 5-alpha reductase inhibitor. *Teratology*; 42:91-100.
- Falsetti L, et al. 1997. Treatment of hirsutism by finasteride and flutamide in women with polycystic ovary syndrome. *Gynecol Endocrinol* 11:251-157.
- Husmann DA, McPhaul MJ. 1991. Time-specific androgen blockade with flutamide inhibits testicular descent in the rat. *Endocrinology*; 129:1409-1416.
- Gupta AK & Talukder M. 2022. Topical finasteride for male and female pattern hair loss: Is it a safe and effective alternative?. *Journal of cosmetic dermatology*, 21(5), 1841-1848.
- Khera M, et al. 2020. Penile vascular abnormalities in young men with persistent side effects after finasteride use for the treatment of androgenic alopecia. *Transl Androl Urol* 9(3): 1201-1209.
- Kohler C, et al. 2007. Effect of finasteride 5mg (Proscar) on acne and alopecia in female patients with normal serum levels of free testosterone. *Gynecol Endocrinol*; 23:142-145.
- Kurzrock EA, et al. 2000. Urethral development in the fetal rabbit and induction of hypospadias: a model for human development. *J Urol* 164(5):1786-1792.
- Laborde, E. and R. E. Brannigan. 2010. Effect of 1-mg dose of finasteride on spermatogenesis and pregnancy. *J Androl*; 31(2): e1-2.
- Lumachi F, Rondinone R. 2003. Use of cyproterone acetate, finasteride, and spironolactone to treat idiopathic hirsutism. *Fertil Steril* 79:942-946.
- Martinez AG, et al. 2011. Effects of in utero exposure to D-004, a lipid extract from *Roystonea regia* fruits, in the male rat: a comparison with finasteride. *J Med Food*. Dec;14(12):1663-9.
- Overstreet JW, et al. 1999. Chronic treatment with finasteride daily does not affect spermatogenesis or semen production in young men. *J Urol* 162:1295-1300.
- Paris JJ, et al. 2011. Inhibition of 5 alpha reductase activity in late pregnancy decreases gestational length and fecundity and impairs object memory and central progesterone milieu of juvenile rat offspring. *J Neuroendocrinol*; 23(11): 1079-90.
- Prahallada S, et al. 1997. Effects of finasteride, a type 2 5-alpha reductase inhibitor, on fetal development in the Rhesus monkey (*Macaca mulatta*). *Teratology*; 55:119-31.
- Propecia prescribing information. 2020. Accessible from <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4e07adb4-7807-47d3-b9a9-2332a3047410#S12.3>
- Ricci G, et al. 2012. Finasteride and fertility: case report and review of the literature. *J Drugs Dermatol*; 11(12):1511-3.
- Rittmaster, RS, 1994. Drug Therapy: Finasteride. *New Engl J Med* 330:120-125.
- Salvarci A, Istanbuluoglu O. 2013. Secondary infertility due to use of low-dose finasteride. *Int Urol Nephrol*; 45(1):83-
- Samplaski MK, et al. 2013. Finasteride use in the male infertility population: effects on semen and hormone parameters. *Fertility and Sterility*; 100:1528-1529.
- Spencer JR, et al. 1991. Effects of flutamide and finasteride on rat testicular descent. *Endocrinology*; 129:741-748.
- Teichert M, et al. 2017. Contraindicated use of 5-alpha-reductase inhibitors in women. *Br J Clin Pharmacol*. 83(2): 429-431
- Wise LD, et al. 1991. Reversible decreases of fertility in male Sprague-Dawley rats treated orally with

finasteride, a 5-alpha-reductase inhibitor. *Reprod Toxicol* 5:353-362

¿Preguntas? Llame al 866.626.6847 | Texto 855.999.3525 | Correo electrónico o chat en MotherToBaby.org .

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de mayo de 2024.

Doxepin

Selected References:

- Ajiji P, et al. 2021. Investigating the efficacy and safety of metronidazole during pregnancy; A systematic review and meta-analysis. ***European Journal of Obstetrics & Gynecology and Reproductive Biology***; **X, 11**, 100128.
- Burtin P, et al. 1995. Safety of metronidazole in pregnancy: a meta-analysis. *Am J Obstet Gynecol* 172(21):525-529.
- Cantu JM & Garcia-Cruz D. 1982. Midline facial defect as a teratogenic effect of metronidazole. *Birth Defects* 18:85-88.
- Caro-Paton T, et al. 1997. Is metronidazole teratogenic? A meta-analysis. *Br J Clin Pharmacol* 44:(2)179-182.
- Cram LF, et al. 2015. Genitourinary infections and their association with preterm labor. *American Family Physician*; 65(2), 241-249.
- Czeizel AE & Rockenbauer M. 1998. A population-based case-control teratologic study of oral metronidazole. *Br J Obstet Gynecol*; 105(3):322-327.
- Finegold SM. 1980. Metronidazole. *Ann Intern Med* 93:585-587.
- Flagyl® Prescribing Information. Available online at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/020334s015lbl.pdf.
- Gilbert NM, et al. 2013. Urinary tract infection as a preventable cause of pregnancy complications: Opportunities, challenges, and a global call to action. *Global Advances in Health and Medicine*; 2(5), 59-69.
- Gray MS, et al. 1961. Further observations on metronidazole (Flagyl). *Br J Vener Dis*; 37:278-9.
- Heisterberg L, Branbjerg PE. 1983. Blood and milk concentrations of metronidazole in mothers and infants. *J*

Perinat Med; 11:114-20.

- Kazy Z, et al. 2005. Teratogenic potential of vaginal metronidazole treatment during pregnancy. Eur J Obstet Gynecol Reprod Biol. 123(2):174-178.
- Koss CA, et al. 2012. Investigation of Metronidazole Use during Pregnancy and Adverse Birth Outcomes. Antimicrob Agents Chemother 56(9): 4800-4805.
- Löfmark S, et al. 2010. Metronidazole is still the drug of choice for treatment of anaerobic infections. Clinical Infectious Diseases, 50(S1), S16-S23.
- Muanda FT, et al. 2017. Use of antibiotics during pregnancy and risk of spontaneous abortion. CMAJ. 189(17):E625-E633.
- Nwosu OC, Bloom K. The safety of metronidazole in pregnancy. Health Care Women Int. 2021;42(4-6):726-738.
- Omranipoor A et al. 2020. Association of antibiotics therapy during pregnancy with spontaneous miscarriage: a systematic review and meta-analysis. **Archives of Gynecology and Obstetrics**302: 5-22.
- Passmore CM, et al. 1988. Metronidazole excretion in human breastmilk and its effect on suckling neonates. British J Clin Pharmacol 26(1):45-51.
- Piper JM, et al. 1993. Prenatal use of metronidazole and birth defects: no association. Obstet Gynecol 82(3):348-352.
- Rosa FW, et al. 1987. Pregnancy outcomes after first trimester vaginitis drug therapy. Obstet Gynecol 69:751-755.
- Sheehy O, et al. 2015. The use of metronidazole during pregnancy: a review of evidence. Curr Drug Saf. 10(2):170-9.
- Workowski KA, Bolan GA. 2015. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep; 64:1-137.

¿Preguntas? Llame al 866.626.6847 | Texto 855.999.3525 | Correo electrónico o chat en [MotherToBaby.org](https://www.MotherToBaby.org) .

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de mayo de 2024.

Doxepin

Selected References:

- Anderson PO. 2021. Monoclonal antibodies during breastfeeding. ***Breastfeeding Medicine***. **16**(8): 591-93.
- Nosedá R, et al. 2024. Safety of Monoclonal Antibodies Inhibiting PCSK9 in Pregnancy: Disproportionality Analysis in VigiBase®. *Clinical pharmacology and therapeutics*, 10.1002/cpt.3269. Advance online publication.
- Praluent® Prescribing Information. Available online at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125559Orig1s000bledt.pdf, Accessed May 28, 2024
- Vuignier Y, et al. 2021. Exposure to alirocumab during the first trimester of pregnancy: A case report. ***Birth Defects Research***. 113(15): 1156-60.

¿Preguntas? Llame al 866.626.6847 | Texto 855.999.3525 | Correo electrónico o chat en [MotherToBaby.org](https://www.mothertobaby.org) .

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de mayo de 2024.

Doxepin

Selected References:

- Anderson PO. 2021. Monoclonal antibodies during breastfeeding. ***Breastfeeding Medicine***. **16**(8): 591-93.
- Deroncourt A., et al. 2023. Fetal and Neonatal Adverse Drug Reactions Associated with Biologics Taken During Pregnancy by Women with Autoimmune Diseases: Insights from an Analysis of the World Health Organization Pharmacovigilance Database (VigiBase®). *BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy*, 37(1), 73-87.
- Kimball AB. 2020. Pregnancy outcomes in women exposed to guselkumab: Experience from the clinical development program. *J Am Acad Dermatol*. 83(6):AB27.

- McMullan P et al. 2024. Safety of dermatologic medications in pregnancy and lactation: An Update-Part I: Pregnancy. ***Journal of the American Academy of Dermatology***.
- Tremfya® Prescribing Information. Available online at <http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/TREMFYA-pi.pdf>. Accessed on May 28, 2024.
- Wolfe C et al., 2024. A Retrospective Review of Pregnancies in our Psoriasis Biologics Cohort. ***Clinical and Experimental Dermatology***. llae106.

¿Preguntas? Llame al 866.626.6847 | Texto 855.999.3525 | Correo electrónico o chat en [MotherToBaby.org](https://www.mothertobaby.org) .

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de mayo de 2024.